Ann: Race Receives Governance Approval for AML EMD & MDS Trial, page-22

RAC emd aml trial.

As far as I am concerned, this trial is the one that I have been longing for so long in the past more than two years.RAC management is very meticulous in their planning for this Trial.

- Input from a very SUCCESSFULLY investigated aml trial 2020 in Israel Sheba1.
- Input from second investigated trial r/r aml currently undergoing in Israel Sheba2.
- Input from vast amount of historical data.
- Input from COH discovery of FTO inhibitor
- Input from BigPharma (Otsuka supply free drugs)

Every thing as above is forming the design and structure for this critical trial. Data will be submitted for approval path."Measure 500 times, cut once.."

Notes:
This trial is unique and the ONLY ONE in the world targeting EMD AML cancer, therefore recruitment should be quick and easy. (Result could lead to our first Partnership)

The First in the World to investigate FTO inhibitor is a NEW potential cancer therapy. (Result could start the bid war among BigPharma)

The trial design is Bayesian so it is driven by events progressively (results) the conclusion of this trial could be a low as 16 patients in total.

One stone kills two birds: (Brilliant Management)

- Stratum1 take care the AML (old pillar 3). - Stratum2 will be the first PoC in HUMAN (old pillar 1 FTO inhibitor).

DYOR GL